Elucidation of the effects of the CYP1A2 deficiency polymorphism in the metabolism of 4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-d]pyrimidine-2-(1H)-one (YM-64227), a phosphodiesterase type 4 inhibitor, and its metabolites in dogs

Drug Metabolism and Disposition

Volumn 34, Issue 11, 2006, Pages 1811-1816

  Tenmizu, Daisuke ^a   Noguchi, Kiyoshi ^a   Kamimura, Hidetaka ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 CYCLOHEXYL 1 ETHYL 7 METHYLPYRIDO[2,3 D]PYRIMIDINE 2(1H) ONE; ALPHA NAPHTHOFLAVONE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A1 ANTIBODY; CYTOCHROME P450 1A2; CYTOCHROME P450 1A2 ANTIBODY; DRUG METABOLITE; ENZYME ANTIBODY; MM 1; MM 2; MM 3; MM 4; MM 5; PHENACETIN; PHENACETIN O DEETHYLASE; PHOSPHODIESTERASE IV INHIBITOR; UNCLASSIFIED DRUG; YM 64227;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CATALYSIS; CONTROLLED STUDY; DOG; DRUG ACTIVITY; DRUG CLEARANCE; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; GENOTYPE; HYDROXYLATION; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; SINGLE NUCLEOTIDE POLYMORPHISM;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; BENZOFLAVONES; CYCLOHEXANES; CYTOCHROME P-450 CYP1A2; DOGS; GENOTYPE; MICROSOMES, LIVER; MOLECULAR STRUCTURE; PHENACETIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIMIDINES;

CANIS FAMILIARIS;

EID: 33751117797     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.011213     Document Type: Article

References (20)

1. Akaike H (1969) Fitting autoregressive models for prediction. Ann Inst Stat Math 21:243-247.
2. Berecz R, de la Rubia A, Dorado P, Fernandez-Salguero P, Dahl ML, and LLerena A (2003) Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol 59:45-50.
3. Campins-Falco P, Herraez-Hernandez R, and Sevillano-Cabeza A (1993) Column-switching techniques for high-performance liquid chromatography of drugs in biological samples. J Chromatogr 619:177-190.
4. Chang TK, Gonzalez FJ, and Waxman DJ (1994) Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 311:437-442.
5. Fried K and Wainer IW (1997) Column-switching techniques in the biomedical analysis of stereoisomeric drugs: why, how and when. J Chromatogr B Biomed Sci Appl 689:91-104.
6. Furuta T, Ohashi K, Kosuge K, Zhao XJ, Takashima M, Kimura M, Nishimoto M, Hanai H, Kaneko E, and Ishizaki T (1996) CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 65:552-561.
7. th American Chemical Society National Meeting, Boston, MA, Aug 23-27, 1998, Book of Abstracts, Part 2: Medical Chemistry, Division 47. American Chemical Society, Washington, DC.
8. Iwatsubo T, Suzuki H, and Sugiyama Y (1999) Determination of the rate-limiting step in the hepatic elimination of YM796 by isolated rat hepatocytes. Pharm Res (NY) 16:110-116.
9. Kagimoto M, Heim M, Kagimoto K, Zeugin T, and Meyer UA (1990) Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 265:17209-17214.
10. Kobayashi K, Nakajima M, Oshima K, Shimada N, Yokoi T, and Chiba K (1997) Involvement of CYP2E1 as a low-affinity enzyme in phenacetin O-deethylation in human liver microsomes. Drug Metab Dispos 27:860-865.
11. Mise M, Hashizume T, Matsumoto S, Terauchi Y, and Fujii T (2004a) Identification of non-functional allelic variant of CYP1A2 in dogs. Pharmacogenetics 14:769-773.
12. Mise M, Yadera S, Matsuda M, Hashizume T, Matsumoto S, Terauchi Y, and Fujii T (2004b) Polymorphic expression of CYP1A2 leading to interindividual variability in metabolism of a novel benzodiazepine receptor partial inverse agonist in dogs. Drug Metab Dispos 32:240-245.
13. Nakajima M, Kobayashi K, Oshima K, Shimada N, Tokudome S, Chiba K, and Yokoi T (1999) Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes. Xenobiotica 29:885-898.
14. Shimada T, Mimura M, Inoue K, Nakamura S, Oda H, Ohmori S, and Yamazaki H (1997) Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Arch Toxicol 71:401-408.
15. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, and Goldstein JA (1996) The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341-349.
16. Tenmizu D, Endo Y, Noguchi K, and Kamimura H (2004a) Identification of the novel canine CYP1A2 1117 C>T SNP causing protein deletion. Xenobiotica 34:835-846.
17. Tenmizu D, Fukunaga Y, Noguchi K, and Kamimura H (2004b) Simultaneous determination of YM-64227, a phosphodiesterase type 4 inhibitor, and its five metabolites in dog plasma by high-performance liquid chromatography with fluorescence detection. Biomed Chromatogr 18:667-672.
18. Tenmizu D, Noguchi K, Kamimura H, Ohtani H, and Sawada Y (2006) The canine CYP1A2 deficiency polymorphism dramatically affects the pharmacokinetics of 4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-d]pyrimidine-2-(1H)-one (YM-64227), a phosphodiesterase type 4 inhibitor. Drug Metab Dispos 34:800-806.
19. Wojcikowski J, Maurel P, and Daniel WA (2006) Characterization of human cytochrome P450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine. Drug Metab Dispos 34:471-476.
20. Zhao XJ and Ishizaki T (1997) The in vitro hepatic metabolism of quinine in mice, rats and dogs: comparison with human liver microsomes. J Pharmacol Exp Ther 283:1168-1176.